MedTrace Logo

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

NCT04016389 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-08-12

No results posted yet for this study

Summary

This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment.

Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer.

The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs used in the treatment of women with cervical cancers.

Conditions

Interventions

DRUG

Cisplatin

Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.

DRUG

Carboplatin

Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.

DRUG

Paclitaxel

Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.

PROCEDURE

Trachelectomy

Surgery to remove the cervix but keep the uterus intact.

Sponsors & Collaborators

  • Hotel Dieu Hospital

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Stephanie Lheureux, M.D. · Princess Margaret Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-11
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04016389 on ClinicalTrials.gov